TIDMSBTX

RNS Number : 7866H

SkinBioTherapeutics PLC

19 November 2018

SkinBioTherapeutics plc

(the "Company")

Result of AGM

SkinBioTherapeutics plc (AIM: SBTX), announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.

For further information, please contact:

 
 SkinBioTherapeutics plc                   Tel: +44 (0) 161 468 2760 
  Dr. Catherine O'Neill, CEO 
  Doug Quinn, CFO 
 Cairn Financial Advisers LLP (Nominated   Tel: +44 (0) 20 7213 0880 
  Adviser) 
  Tony Rawlinson / Sandy Jamieson 
  / Richard Nash 
 Turner Pope Investments (Joint            Tel: +44 (0) 20 3621 4120 
  Broker) 
  Ben Turner / James Pope 
 Northland Capital Partners (Joint         Tel: +44 (0) 20 3861 6625 
  Broker) 
  Dugald Carlean 
 Instinctif Partners                       Tel: +44 (0) 20 7457 2020 
  Melanie Toyne-Sewell / Deborah            SkinBio@instinctif.com 
  Bell

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGFKCDDBBDDPDD

(END) Dow Jones Newswires

November 19, 2018 07:30 ET (12:30 GMT)

Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Skinbiotherapeutics Charts.
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Skinbiotherapeutics Charts.